Percutaneous catheter drainage versus needle aspiration for liver abscess: a systematic review and meta-analysis of efficacy and safety.

Eur J Gastroenterol HepatolSep 30, 2026 (epub)
Clinical ResearchGastroenterologyGeneral Surgery

Dandan Xu, Deying Zeng

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of percutaneous catheter drainage (PCD) versus needle aspiration (PNA) for liver abscesses in 1425 adults. The study found that PCD significantly improved treatment success rates compared to PNA, with an odds ratio of 4.12 (95% CI = 2.01-8.45; P < 0.001).

Key findings

  • PCD had a treatment success rate significantly higher than PNA, with an odds ratio of 4.12.
  • No significant difference in overall complication rates between PCD and PNA (OR = 1.02).
  • Subgroup analyses confirmed the benefit of PCD across different abscess sizes and etiologies.

Why it matters

Understanding the comparative effectiveness of PCD and PNA is crucial for clinicians managing liver abscesses, as it informs treatment decisions and can improve patient outcomes.

Source

PubMed · PMID 42743010

Published in Eur J Gastroenterol Hepatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.